cms.bioaccessla.com

Clinical Trial Protocol Development: A Step-by-Step Walkthrough for FIH Medical Devices

Written by

Julio Martinez-Clark

in

WordPress Category: Navigating Regulatory Landscapes in Latin America

Writing a clinical trial protocol for a first-in-human (FIH) medical device study is not a documentation exercise. It is a strategic decision that shapes your regulatory pathway, your site selection, your enrollment timeline, and ultimately whether your data will be accepted by FDA. Get it right, and you have a submission-ready evidence package. Get it wrong, and you are rewriting sections after your first ethics review, burning weeks you cannot afford.

This walkthrough covers what founders and clinical operations leads need to understand before a single word of their protocol is drafted.

Why Protocol Development Is Different for FIH Medical Devices

FIH drug trials follow a relatively standardized dose-escalation framework. Medical device FIH studies are more variable. The protocol must account for device-specific risks, operator learning curves, procedural endpoints, and the regulatory route the sponsor intends to pursue — whether that is IDE, 510(k), De Novo, PMA, or HDE.

FDA's investigational device exemption guidance and ISO 14155:2020 — the international GCP standard for medical device trials — together define the architecture your protocol must satisfy. If your study will generate data used in a US submission, structuring under ISO 14155 from the start is not optional. It is how you ensure the data qualifies under FDA 21 CFR 812.28 for foreign clinical data acceptance.

That regulatory anchor needs to be set before protocol drafting begins, not after.

Step 1: Align on Your US Regulatory Pathway First

Before writing a single inclusion criterion, confirm which FDA pathway the study data will support. Protocol design follows from that answer.

  • IDE pathway: Your protocol must satisfy FDA's investigational device exemption requirements. For studies conducted outside the US, you will need to demonstrate that the study design, GCP compliance, and data collection meet the standards FDA applies to foreign clinical data under 21 CFR 812.28.
  • 510(k) or De Novo: The protocol must define substantial equivalence endpoints or performance criteria that map directly to your predicate or device classification.
  • PMA or HDE: Expect a more rigorous statistical plan, longer follow-up windows, and a higher bar for safety documentation.

Drafting a protocol to a generic GCP standard without first confirming the regulatory pathway is one of the most common and costly mistakes in early-stage device development. You end up with data that is scientifically valid but regulatorily incomplete.

Step 2: Define Study Objectives and Endpoints Precisely

The primary objective of a FIH device study is typically safety and feasibility, not efficacy. That distinction matters for how you structure your endpoints.

Primary endpoints should capture:

  • Device-related adverse events and serious adverse events (SAEs)
  • Technical success at the procedural level
  • Early performance indicators tied to the device's mechanism of action

Secondary endpoints might include:

  • Subject-reported outcomes at defined follow-up intervals
  • Imaging or biomarker data supporting performance claims
  • Operator assessment of usability and handling

Be specific. "Safety will be assessed" is not an endpoint. "Incidence of device-related SAEs at 30 days post-procedure" is. Vague endpoints create ambiguity during data analysis and give ethics committees a reason to request revisions.

Step 3: Write Eligibility Criteria That Reflect Real Patient Populations

Overly restrictive eligibility criteria are the single largest driver of enrollment delays in FIH device trials. Founders often write criteria that reflect their ideal study subject rather than the patients who actually present at clinical sites.

A few practical guidelines:

  • Anchor criteria to your intended indication. If your device is intended for a broad population, your criteria should not narrow to a subgroup so specific that enrollment stretches to 18 months.
  • Exclude for safety, not convenience. Every exclusion criterion should have a documented safety or scientific rationale. Ethics committees will ask.
  • Pressure-test criteria against site feasibility data. If your CRO has pre-qualified sites in your target geography, they should be able to tell you whether the criteria are achievable given the patient populations those sites actually see.

In jurisdictions like Panama, El Salvador, Chile, and the Dominican Republic, patient populations are often well-suited for FIH feasibility work, with disease prevalence and site infrastructure that support enrollment within realistic timelines. Even so, your criteria still need to match the site's actual patient flow.

Step 4: Design the Safety Monitoring Plan

For a FIH device study, the safety monitoring plan is not a boilerplate appendix. It is a core section that regulators and ethics committees scrutinize carefully.

Your plan should define:

  • Stopping rules: Specific, measurable criteria that would pause or terminate the study
  • DSMB or independent safety review: Whether one is required, how often it convenes, and what data it reviews
  • Adverse event reporting timelines: Expedited reporting requirements for SAEs, including timelines to the sponsor, ethics committee, and regulatory authority
  • Device deficiency reporting: ISO 14155 requires a clear distinction between adverse events and device deficiencies — your protocol needs to reflect that

Sponsors running multi-site studies increasingly use dedicated ICSR (Individual Case Safety Report) platforms to manage regulatory submissions across jurisdictions, which reduces the risk of missed reporting windows during active enrollment.

Step 5: Build the Statistical Analysis Plan Into the Protocol From the Start

Many early-stage sponsors treat the statistical analysis plan (SAP) as something to write after enrollment closes. That is the wrong sequence.

Your protocol should include, at minimum:

  • Sample size justification: For FIH feasibility studies, this is often based on precision estimates rather than power calculations — but you still need a documented rationale
  • Primary analysis method: How you will analyze your primary safety and feasibility endpoints
  • Handling of missing data: Especially relevant for device studies with procedural endpoints where some subjects may not complete follow-up

FDA reviewers will look at whether your analysis was pre-specified. A post-hoc safety analysis carries less weight than one defined prospectively in the protocol.

Step 6: Address Regulatory Submission Requirements for Your Target Jurisdiction

If you are running your FIH study in Latin America, your protocol needs to satisfy both the local regulatory authority and FDA's foreign data acceptance standards simultaneously.

In the four jurisdictions where bioaccess® operates, ethics and regulatory approvals take 30 to 90 days. That speed advantage is only realized if your protocol is structured correctly from submission. A document that requires multiple revision cycles with MINSA/CNBI in Panama or SRS/CNEIS in El Salvador will erode the timeline advantage those jurisdictions offer.

Key requirements to address in the protocol:

  • Informed consent language: Must satisfy local ethics committee requirements and be available in the local language
  • Investigator qualifications: Document the PI's experience with the device type and procedure
  • Site infrastructure requirements: Define what the site needs to have in place — equipment, staff, and follow-up capabilities
  • Data management standards: If the data will be submitted to FDA, your EDC and data collection instruments need to meet the requirements for foreign clinical data acceptance under 21 CFR 812.28

Step 7: Write the Protocol Amendment Process Into the Document

FIH studies generate new information. Your protocol will almost certainly need at least one amendment — whether to adjust stopping rules based on early safety data, modify follow-up windows, or refine eligibility criteria after the first few enrollments.

Define the amendment process in the protocol itself:

  • What types of changes require ethics committee re-approval versus administrative notification
  • How protocol deviations will be documented and reported
  • Who has authority to approve amendments on the sponsor side

Ethics committees in Latin American jurisdictions, like those anywhere, expect sponsors to have a clear governance process for protocol changes. Having it documented upfront prevents delays when an amendment is actually needed.

How the FIH-12™ Program Structures Protocol Development

For startups running their first device trial, the protocol development process described above is often unfamiliar territory. The FIH-12™ program at bioaccess® integrates protocol development as one of nine structured workstreams, alongside FDA strategy alignment, site activation, patient enrollment, data management, and final evidence package delivery.

One accountable team manages all nine workstreams, which means the protocol is written with the site network, enrollment feasibility, and submission requirements already factored in — rather than developed in isolation and handed off to execution teams who find problems later.

If you are 12 to 24 months from needing your first human dataset and want a preliminary view of your country route, timeline range, and evidence package requirements, the FIH Launch Planner at bioaccessla.com generates a preliminary estimate based on your device class in six questions.

Common Protocol Development Mistakes in FIH Device Studies

A few patterns appear repeatedly in early-stage device programs:

Starting protocol development before regulatory strategy is confirmed. The protocol should follow from the regulatory pathway, not the other way around.

Writing endpoints that cannot be measured at your sites. If your primary endpoint requires imaging equipment or lab infrastructure that your sites do not have, you have an enrollment problem before you start.

Underestimating the ethics committee review process. Even in fast-approval jurisdictions, a poorly structured protocol will generate questions that extend your timeline. The 30 to 90 day approval window in Panama, El Salvador, Chile, and the Dominican Republic assumes a submission-ready document.

Separating the statistical plan from the protocol. Pre-specified analysis is a credibility signal for FDA reviewers. Build it in from the start.

Treating the protocol as a static document. Plan for amendments. They are not a sign that the study is failing — they are a normal part of FIH execution.

FAQs

What is the difference between a clinical trial protocol for a medical device versus a drug?
Drug protocols typically follow dose-escalation frameworks with pharmacokinetic endpoints. Medical device protocols focus on procedural safety, technical success, operator performance, and device-specific adverse events. They must also comply with ISO 14155 for GCP — the applicable standard for medical device trials — rather than the ICH E6 framework used for drugs.

Does a FIH protocol written for a Latin American study need to meet FDA standards?
Yes, if the data will be used in a US regulatory submission. Under FDA 21 CFR 812.28, foreign clinical data is acceptable when the study was conducted under GCP standards equivalent to those FDA requires. Structuring the protocol under ISO 14155 and aligning data collection with FDA's foreign data acceptance requirements from the start is how you ensure the data is usable for your IDE or 510(k) submission.

How long does it typically take to develop a FIH protocol for a medical device?
Timelines vary based on device complexity, regulatory pathway, and how much pre-clinical data is already available to inform safety parameters. Within the FIH-12™ program, protocol development is one of nine structured workstreams managed by a single accountable team, with the goal of a submission-ready evidence package within 12 months from program start.

What happens if the ethics committee requests protocol revisions?
Revision requests are normal and should be anticipated. The key is having a protocol that is well-structured enough to minimize revision cycles. In the four jurisdictions where bioaccess® operates, the 30 to 90 day approval window assumes a submission-ready document. Poorly structured protocols extend that window and erode the timeline advantage those jurisdictions offer.

How should sample size be justified for a FIH feasibility study?
For FIH device studies, sample size justification is typically based on precision estimates or feasibility criteria rather than statistical power calculations. You need a documented rationale explaining why the number of subjects is sufficient to characterize safety and feasibility for the intended use. FDA reviewers will look for this justification in the protocol.

What is ISO 14155 and why does it matter for FIH device protocols?
ISO 14155:2020 is the international standard for good clinical practice in medical device investigations. It defines requirements for protocol content, ethics committee submissions, informed consent, adverse event reporting, and data management. Structuring your FIH protocol under ISO 14155 is how you demonstrate GCP compliance to both local regulatory authorities in Latin America and FDA when submitting foreign clinical data.

When should a Data Safety Monitoring Board be included in a FIH device protocol?
A DSMB is not required for all FIH device studies, but it is strongly advisable for studies involving novel mechanisms, high-risk device classifications, or vulnerable patient populations. The protocol should define whether a DSMB is included, how often it convenes, what data it reviews, and what authority it has to recommend study modifications or early termination.

Start With the Right Foundation

A clinical trial protocol is the document that every downstream decision in your study depends on. Site selection, enrollment planning, data management, ethics submissions, and the final evidence package all trace back to choices made during protocol development.

For medical device founders running their first FIH study, the most important thing to get right is the regulatory anchor. Know your FDA pathway before you write your first endpoint. Structure your data collection for foreign data acceptance from day one. And build your safety monitoring plan with the same rigor you would apply to a pivotal trial — because for many FIH studies, this data will eventually support one.

If you are in the early stages of planning your FIH program, bioaccess® manages protocol development as part of a fully integrated nine-workstream engagement across Panama, El Salvador, Chile, and the Dominican Republic, where regulatory approvals take 30 to 90 days.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

More posts